not tagged
Miltenyi Biomedicine
['dlbcl']
interim results from daly ii of zamto-cel presented by with dual cd19/cd20 car for dlbcl in the 3l+ setting; 22 pts treated with promising 80+% orr and cr rate in 50s although very early data #17icml; also no prior car exposure among pts which is a remaining need 
Heme/Onc fellow @UCCancerCenter interested in aggressive lymphoma, novel therapeutics, and cellular therapies #lymsm #TcellRx. Views are my own.